Zoetis Inc. (NYSE:ZTS) Shares Bought by Texas Capital Bank Wealth Management Services Inc

Texas Capital Bank Wealth Management Services Inc raised its holdings in Zoetis Inc. (NYSE:ZTS) by 7.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,991 shares of the company’s stock after purchasing an additional 2,859 shares during the quarter. Texas Capital Bank Wealth Management Services Inc’s holdings in Zoetis were worth $7,106,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Asset Dedication LLC raised its holdings in Zoetis by 4.8% in the 2nd quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after buying an additional 54 shares during the period. Angeles Wealth Management LLC boosted its position in shares of Zoetis by 3.5% during the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after purchasing an additional 56 shares during the period. Forza Wealth Management LLC boosted its position in shares of Zoetis by 1.8% during the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock worth $574,000 after purchasing an additional 58 shares during the period. L. Roy Papp & Associates LLP increased its holdings in Zoetis by 2.8% in the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock valued at $385,000 after purchasing an additional 60 shares during the last quarter. Finally, Edge Capital Group LLC raised its position in Zoetis by 3.7% in the second quarter. Edge Capital Group LLC now owns 1,786 shares of the company’s stock valued at $310,000 after purchasing an additional 64 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.1 %

ZTS stock opened at $194.70 on Friday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company’s 50 day moving average price is $186.04 and its 200 day moving average price is $174.84. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The firm has a market capitalization of $88.84 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 2.97 and a beta of 0.88.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the business earned $1.41 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of research reports. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus lifted their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.